In a report issued on November 28, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on Ascendis Pharma (ASND), with a price target of $84. The company’s shares closed on Friday at $67.51.
According to TipRanks.com, Gilson is ranked #559 out of 5130 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ascendis Pharma.
See today’s analyst top recommended stocks >>
The company has a one-year high of $76.99 and a one-year low of $36.07. Currently, Ascendis Pharma has an average volume of 118.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.
